Curis Presents Realignment at BIO CEO & Investor Conference
CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 20, 2002--Curis, Inc. (Nasdaq: CRIS - news) today announced that Daniel R. Passeri, President and Chief Executive Officer, will present at the BIO CEO & Investor Conference in New York on Thursday, February 21, 2002 at 4:40 pm EST.
Curis will give updates on its research and development programs, product focus and expected milestones, as affected by the Company's announcement of its strategic realignment last week. Curis plans to focus its resources on its proprietary signaling pathways and stem cell technologies, including the Bone Morphogenic Protein (BMP) and the Hedgehog family of products. These and further updates will be outlined in Curis' slideshow presentation at BIO CEO, which will also be posted at Curis' website, www.curis.com.
About Curis, Inc.
Curis, Inc. is generating therapies that regulate the pathways used by the body to maintain and restore health. The company focuses on signaling pathways that govern the proliferation and differentiation of cells. These same pathways control maintenance, repair, and regeneration of tissues and organs from infancy through old age. This approach has created an approved product for bone regeneration and enables Curis to build a portfolio of product candidates in neurology, kidney disease, and cancer. For more information, please visit the Curis web site at www.curis.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements address a variety of subjects, including, for example, cost savings, cash burn rate, operating capital requirements, operating efficiencies, strategic collaboration efforts and product development efforts. Statements in this press release that state Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. The matters discussed in this press release also involve risks and uncertainties that may cause Curis' actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: Curis' need for partnerships to move forward its cell therapy programs, the early stage of product development of Curis' retained programs, uncertainties related to clinical trials, uncertainties related to Curis' ability to raise additional capital, changes in or an inability to execute Curis' realigned business strategy and other risk factors described from time to time in Curis' periodic reports and registration statements filed with the Securities and Exchange Commission, including, without limitation, Curis' Annual Report on Form 10-K for the year ended December 31, 2000 filed on March 30, 2001 and the Company's Post Effective Amendment No. 1 on Form S-3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 10, 2001. Curis cannot guarantee any future results, levels of activity, performance, or achievements. Moreover, neither Curis nor anyone else assumes responsibility for the accuracy and completeness of any forward-looking statements. Curis undertakes no obligation to update any of the forward-looking statements after the date of this press release.
--------------------------------------------------------------------------------
Contact:
For Curis, Inc.
Henry McCusker
(617) 503-6641
or
For Noonan/Russo Communications, Inc.
Melissa Wainberg (media)
(212) 696-4455, ext. 220 |
